НОВЫЕ МАРКЕРЫ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ: ЗНАЧЕНИЕ ДЛЯ ДИАГНОСТИКИ И ПРОГНОЗИРОВАНИЯ NT-proBNP И ИНТЕРЛЕЙКИНОВЫХ РЕЦЕПТОРОВ – ЧЛЕНОВ СЕМЕЙСТВА ST2

The article discusses the use of new biomarkers for assessing the severity of the clinical course and the prognosis of chronic heart failure. In recent decades, prospective possibilities for using biomarkers as the part of early personalized diagnosis of cardiovascular disease have been actively studied to optimize the diagnosis process, patients’ prognosis and increase the effectiveness of therapy for chronic heart failure. New biomarkers are highly sensitive mediators for evaluation of pathogenetic mechanisms of the development and progression of chronic heart failure. Plasma levels of a new biomarker expressed by cardiomyocytes, fibroblasts and endothelial cells, a member of the IL-1 family of soluble isoform ST2 (sST2), which ligand is IL-33 cytokine, is of particular interest. Risk personification using NT-proBNP and ST2 biomarkers allows identifying themostvulnerablepatients for further monitoringand intensification of therapeutic interventions.